The global biomedical industry is developing from a high-tech industry with development potential to a high-tech pillar industry, 

and the biomedical industry is also the third largest industry after the automobile and machinery manufacturing industry.

Many countries have also taken the biomedical industry as one of the strategic industries for priority development in the 21st century. 

The government attaches great importance to the development of the biomedical industry, 

and promotes biotechnology innovation through the implementation of a series of comprehensive scientific and technological plans,

 vigorously supports innovative biotechnology enterprises, and cultivates biomedicine as a new economic growth point.

At the same time, various countries also regard the biomedical industry as an important means to improve the competitiveness of stock prices,

 and formulate development plans, strengthen leadership, recruit talents, and increase policy support and capital investment for the biomedical industry.

Similar to the entire pharmaceutical industry, the biomedical industry also has the characteristics of high investment, high yield, high risk, and long cycle,

 and requires high investment as a condition for industrial entry and sustainable development. 

For example, the long cycle is a significant feature of the biomedical industry, from laboratory research, pilot production, clinical trials, 

large-scale production to commercialization, all stages need to pass the drug approval process.

Therefore, a biomedical variety from preclinical research to the market, generally takes 5 to 10 years. For biopharmaceutical companies, 

it generally takes a long time from establishment to profitability.

It is reported that the more successful foreign biopharmaceutical enterprises from the establishment to the listing of an average of 4 years, 

and from the listing to the average of 7 years, after the profit, the enterprise will appear non-linear growth.

In order to minimize costs, establish a global production and sales network, but also in order to obtain new drugs or directly master new technologies, 

the global merger and acquisition and restructuring boom in the biomedical industry has greatly improved the ability of major biomedical companies to seize the market,

 monopolize technology, and obtain excess profits.

Driven by these upsurge, after years of development and market competition, coupled with the government's timely guidance,

 many developed countries have gradually formed biological industry clusters in areas with intensive technology, talent and capital, 

and thus formed a relatively complete biomedical industry chain and industrial cluster.

For example, the United States has formed five biotechnology industry regions: San Francisco, Boston, Washington, North Carolina, and San Diego. 

Another example is the Cambridge Genome Park in the United Kingdom, the Gene Valley in the southern suburbs of Paris in France, 

the biotechnology demonstration zone in Germany, and the Bangalore Biological Park in India. 

These biotechnology industrial clusters have emerged in the industrial institutions of these countries and regions,

 and have made important contributions to expanding the scale of the biomedical industry and enhancing the competitiveness of the industry.

From the perspective of the world, the general pattern of the development of the global biomedical industry has formed, 

and the industry is concentrated in three major centers. The United States biomedical research and development strength and industrial development leading the world,

 and become the center of the biomedical industry. With its solid industrial base and technological advantages, 

Europe follows the United States and is at the forefront of the world.

In addition, with the increasing aging of the population, although the start of Japan's biomedical field is later than that of European and American countries, 

it is developing rapidly. In addition to Japan, under the active cultivation and support of the government, the biomedical industry in China, India,

 Singapore and other Asian countries has also achieved rapid development in recent years. 

The industry believes that Asia has become another major biomedical industry center in addition to North America and Europe.

(Source:中国制药网)
Article link:中国制药网 http://www.zyzhan.com/news/Detail/72393.html